**SECURITIES
      AND EXCHANGE COMMISSION**


**WASHINGTON,
      D.C. 20549**





**FORM
      10-QSB**





Quarterly
      Report under Section 13 or 15 (d) of


Securities
      Exchange Act of 1934





For
      Period
      ended March 31, 2007





Commission
      File Number 0-32201





**BIO
      MATRIX SCIENTIFIC GROUP, INC.**


(Exact
      name of registrant as specified in its charter)




DELAWARE
            33-0824714(State
                of Incorporation)
            (I.R.S.
                Employer Identification No.)8885
                Rehco Road, San Diego, California
            92121(Address
                of Principal Executive Offices)
            (Zip
                Code)





(619)
      398-3517


(Registrant's
      telephone number, including area code)










Check
      whether the registrant (1) has filed all reports required to be filed
      by


Section
      13
      or 15 (d) of the Securities Exchange Act of 1934 during the
      preceding


12
      months
      (or for such shorter period that the registrant was required to
      file


such
      reports), and (2) has been subject to such filing requirements for the
      past


90
      days.
      Yes [X] No [ ]





There
      were
      19,295,042 shares of Common Stock outstanding as of April 5, 2007 **.**















1




**Chang
      G. Park, CPA, Ph. D.**


**t** **371 E STREET** **t** **CHULA VISTA** **t** **CALIFORNIA 91910-2615** **t**


**t** **TELEPHONE (858)722-5953** **t** **FAX (858) 408-2695** **t** **FAX (858) 764-5480**


**t** **E-MAIL changgpark@gmail.com** **t**








**Report
      of Independent Registered Public Accounting Firm**








To
      the
      Board of Directors of


Bio-Matrix
      Scientific Group, Inc. and Subsidiary


(Formerly
      Tasco International, Inc.)


(A
      Development Stage Company)








We
      have
      reviewed the consolidated accompanying balance sheet of Bio-Matrix Scientific
      Group, Inc. and Subsidiary (Formerly Tasco International, Inc) (A Development
      Stage “Company”) as of March 31, 2007, and the related consolidated statements
      of operation, changes in stockholders’ equity, and cash flows for the six months
      and three months ended March 31, 2007; and for the period from October 6, 1998
      (inception) through March 31, 2007. These financial statements are the
      responsibility of the Company’s management.





We
      conducted our review in accordance with the standards of the Public Company
      Accounting Oversight Board (United States). A review of interim financial
      information consists principally of applying analytical procedures to financial
      data and making inquiries of persons responsible for financial and accounting
      matters. It is substantially less in scope than an audit conducted in accordance
      with the standards of the Public Company Accounting Oversight Board, the
      objective of which is the expression of an opinion regarding the financial
      statements taken as a whole. Accordingly, we do not express such an
      opinion.





Based
      on
      our review, we are not aware of any material modifications that should be made
      to the consolidated financial statements referred to above for them to be in
      conformity with generally accepted accounting principles.





The
      accompanying consolidated financial statements have been prepared assuming
      that
      the Company will continue as a going concern. As discussed in Note 5 to the
      consolidated financial statements, the Company is currently in the development
      stage. Because of the Company’s current status and limited operations there is
      substantial doubt about its ability to continue as a going concern. Management’s
      plans in regard to its current status are also described in Note 5. The
      financial statements do not include any adjustments that might result from
      the
      outcome of this uncertainty.










/s/Chang
      G
      Park


__________________________


Chang
      G.
      Park, CPA





May
      8,
      2007


Chula
      Vista, California








2


**PART
      I.**


**BIO-MATRIX
                  SCIENTIFIC GROUP, IINC. AND SUBSIDIARY****(FORMARLY
                  TASCO INTERNATIONAL)****(A
                  Development Stage Company)****Consolidated
                  Balance Sheets****ASSETS****As
                  of March 31, 2007 (Unaudited)**
              
              
              **As
                  of September 30, 2006****CURRENT
                  ASSETS**Cash
              
              $
              147,705
              
              $
              22,641Employee
                  Receivable
              
              
              3,000Pre-paid
                  Expenses
              
              
              23,727
              
              
              20,207**Total
                  Current Assets**
              
              
              174,432
              
              
              42,848**PROPERTY
                  & EQUIPMENT**
              
              
              364,737
              
              
              340,557**GOODWILL****Intangible
                  Assets/Technology**
              
              
              -**Total
                  Other Assets**
              
              
              25,726
              
              
              29,127**TOTAL
                  ASSETS**
              
              $
              **564,895**
              
              $
              **412,532****LIABILITIES
                  AND STOCKHOLDERS' EQUITY****CURRENT
                  LIABILITIES**Accounts
                  payable
              
              $
              3,945
              
              $
              91,079Loans
                  from former parent
              
              
              -
              
              
              1,195,196Due
                  To/ From New Parent
              
              
              -
              
              
              -Notes
                  Payable
              
              
              321,562
              
              
              148,952Accrued
                  Payroll
              
              
              -
              
              
              -Accrued
                  Payroll Taxes
              
              
              14,545
              
              
              16,460Accrued
                  Interest
              
              
              13,258
              
              
              1,368Accrued
                  expenses
              
              
              -
              
              
              -**Total
                  Current Liabilities**
              
              
              353,310
              
              
              1,453,055**LONG
                  TERM LIABILITIES**
              
              
              -
              
              
              -**TOTAL
                  LIABILITIES**
              
              
              353,310
              
              
              1,453,055**STOCKHOLDERS'
                  EQUITY**Preferred
                  Stock ($.0001 par value authorized20,000,000
                  shares authorized; noneissued
                  and outstanding.)Common
                  Stock, ($.0001 par value authorized80,000,000
                  shares authorized; 17,996,619 and 13,385,000shares
                  issued and outstanding as of March 31, 2007 and September 30, 2006,
                  respectively
              
              
              1,800
              
              
              1339Additional
                  paid in Capital
              
              
              32,609,035
              
              
              30,375,584Deficit
                  accumulated during the development stage
              
              
              (32,399,250
              )
              
              (31,417,446
              )**Total
                  Stockholders' Equity (Deficit)**
              
              $
              211,585
              
              $
              (1,040,523
              )**TOTAL
                  LIABILITIES****&
                  STOCKHOLDERS' EQUITY**
              
              $
              **564,895**
              
              $
              **412,532**
  The
        accompanying notes are an integral part of these financial
        statements
 3
  **BIO-MATRIX
                  SCIENTIFIC GROUP, IINC. AND SUBSIDIARY****(FORMARLY
                  TASCO INTERNATIONAL)****(A
                  Development Stage Company)****Consolidated
                  Statement of Operations**
                **(Unaudited)**
  **Inception****(October
                  6, 1998)******
              
              
              **3
                  Months Ended**
              
              
              **3
                  Months Ended**
              
              
              **6
                  Months Ended**
              
              
              **6
                  Months Ended**
              
              
              **through****March
                  31,**
              
              
              **March
                  31**
              
              
              **March
                  31,**
              
              
              **March
                  31**
              
              
              **March
                  31,****2007**
              
              
              **2006**
              
              
              **2007**
              
              
              **2006**
              
              
              **2007****REVENUES**Sales
              
              $
              -
              
              $
              -
              
              $
              -
              
              $
              -
              
              $
              1,000**Total
                  Revenues**
              
              
              -
              
              
              -
              
              
              -
              
              
              
              
              
              1,000**COSTS
                  AND EXPENSES**
              
              
              -Research
                  and Development
              
              
              60,604
              
              
              
              
              
              169,092
              
              
              
              
              
              196,767General
                  and administrative
              
              
              217,090
              
              
              1,633
              
              
              441,763
              
              
              1,883
              
              
              1,268,458Depreciation
                  and amortization
              
              
              333
              
              
              
              
              
              667
              
              
              
              
              
              1,000Consulting
                  and professional fees
              
              
              228,321
              
              
              
              
              
              354,161
              
              
              
              
              
              1,144,796Impairment
                  of goodwill & intangibles
              
              
              -
              
              
              
              
              
              -
              
              
              
              
              
              29,777,222**Total
                  Costs and Expenses**
              
              
              506,348
              
              
              1,633
              
              
              965,683
              
              
              1,883
              
              
              32,388,243**OPERATING
                  LOSS**
              
              
              (506,348
              )
              
              (1,633
              )
              
              (965,683
              )
              
              (1,883
              )
              
              (32,387,243
              )**OTHER
                  INCOME & (EXPENSES)**Interest
                  Expense
              
              
              (9,509
              )
              
              
              
              
              (16,354
              )
              
              
              
              
              (17,722
              )Other
                  Expense
              
              
              (73
              )
              
              1
              
              
              (73
              )
              
              13
              
              
              (73
              )Interest
                  Income
              
              
              306
              
              
              
              
              
              306
              
              
              
              
              
              345Other
                  income
              
              
              -
              
              
              
              
              
              -
              
              
              
              
              
              5,443**Total
                  Other Income & (Expenses)**
              
              
              (9,276
              )
              
              1
              
              
              (16,121
              )
              
              13
              
              
              (12,007
              )**NET
                  INCOME (LOSS)**
              
              $
              (515,624
              )
              $
              **(1,632**
              **)**
              
              **(981,804**
              **)**
              **$**
              **(1870**
              **)**
              $
              **(32,399,250**
              **)****BASIC
                  AND DILUTED EARNINGS (LOSS) PER SHARE****BASIC
                  AND DILUTED EARNINGS (LOSS) PER SHARE**
              
              $
              (0.03
              )
              $
              **(0.00**
              **)**
              
              **(0.06**
              **)**
              **$**
              **(0.00**
              **)**
              $
              -**WEIGHTED
                  AVERAGE NUMBER OF****COMMON
                  SHARES OUTSTANDING**
              
              
              **16,947,346**
              
              
              **12,780,000**
              
              
              **16,102,133**
              
              
              **12.780,000**
              
              
              -
  The
        accompanying notes are an integral part of these financial
        statements
 4
 **BIO-MATRIX
                    SCIENTIFIC GROUP INC. AND SUBSIDIARY****(FORMERLY
                    TASCO INTERNATIONAL, INC.)****Consolidated
                    Statement of Stockholders' Equity****From
                    October 6, 1998 through March 31, 2007**
                  **(Unaudited)**
  **Additional**
                
                
                **Deficit
                    Accumulated****Common**
                
                **Paid-in**
                
                
                **During
                    the****Shares**
                
                
                **Amount**
                
                
                **Capital**
                
                
                **Development
                    Stage**
                
                
                **Total**Stock
                    issued for cash October 6, 1998
                
                
                1,000,000
                
                $
                100
                
                $
                (90
                )
                $
                
                
                $
                10Stock
                    issued for cash October 9, 1998
                
                
                1,300,000
                
                
                130
                
                
                1,170
                
                
                
                
                
                1,300Stock
                    issued for cash October 9, 1998
                
                
                190,000
                
                
                19
                
                
                171
                
                
                
                
                
                190Stock
                    issued for cash April 1, 1999
                
                
                290,000
                
                
                29
                
                
                261
                
                
                
                
                
                290Net
                    Loss October 6,1998 (inception)
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 1999
                
                
                
                
                
                
                
                
                
                
                
                (295
                )
                
                (295
                )**Balance
                    September 30, 1999**
                
                
                **2,780,000**
                
                
                **278**
                
                
                **1,512**
                
                
                **(295**
                **)**
                
                **1,495**Stock
                    issued for cash October 19, 1999
                
                
                10,000,000
                
                
                1,000
                
                
                9,000
                
                
                
                
                
                10,000Net
                    Loss October 1,1999
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 2000
                
                
                
                
                
                
                
                
                
                
                
                (367
                )
                
                (367
                )**Balance
                    September 30, 2000**
                
                
                **12,780,000**
                
                
                **1,278**
                
                
                **10,512**
                
                
                **(662**
                **)**
                
                **11,128**Net
                    Loss October 1, 2000
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 2001
                
                
                
                
                
                
                
                
                
                
                
                (11,028
                )
                
                (11,028
                )**Balance
                    September 30, 2001**
                
                
                **12,780,000**
                
                
                **1,278**
                
                
                **10,512**
                
                
                **(11,690**
                **)**
                
                **100**Net
                    Loss October 1, 2001
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 2002
                
                
                
                
                
                
                
                
                
                
                
                (4,257
                )
                
                (4,257
                )**Balance
                    September 30, 2002**
                
                
                **12,780,000**
                
                
                **1,278**
                
                
                **10,512**
                
                
                **(15,947**
                **)**
                
                **(4,157**
                **)**Net
                    Loss October 1, 2002
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 2003
                
                
                
                
                
                
                
                
                
                
                
                (4,328
                )
                
                (4,328
                )**Balance
                    September 30, 2003**
                
                
                **12,780,000**
                
                
                **1,278**
                
                
                **10,512**
                
                
                **(20,275**
                **)**
                
                **(8,485**
                **)**Contributed
                    Capital
                
                
                
                
                
                
                
                
                12,362
                
                
                
                
                
                12,362Net
                    Loss October 1, 2003
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 2004
                
                
                
                
                
                
                
                
                
                
                
                (7,974
                )
                
                (7,974
                )**Balance
                    September 30, 2004**
                
                
                **12,780,000**
                
                
                **1,278**
                
                
                **22,874**
                
                
                **(28,249**
                **)**
                
                **(4,097**
                **)**Contributed
                    Capital
                
                
                
                
                
                
                
                
                9,021
                
                
                
                
                
                9,021Net
                    Loss October 1, 2004
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 2005
                
                
                
                
                
                
                
                
                
                
                
                (6,667
                )
                
                (6,667
                )**Balance
                    September 30, 2005**
                
                
                **12,780,000**
                
                
                **1,278**
                
                
                **31,895**
                
                
                **(34,916**
                **)**
                
                **(1,743**
                **)**Stock
                    Cancelled June 13, 2006
                
                
                (10,000,000
                )
                
                (1,000
                )
                
                
                
                
                
                
                
                (1,000
                )Stock
                    issued June 13, 2006
                
                
                10,000,000
                
                
                1,000
                
                
                28,999,000
                
                
                
                
                
                29,000,000Stock
                    issued for services
                
                
                305,000
                
                
                31
                
                
                759,719
                
                
                
                
                
                759,750Stock
                    issued for Compensation
                
                
                300,000
                
                
                30
                
                
                584,970
                
                
                
                
                
                585,000Net
                    Loss October 1, 2005
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    September 30, 2006
                
                
                
                
                
                
                
                
                
                
                
                (31,382,530
                )
                
                (31,382,530
                )**Balance
                    September 30, 2006**
                
                
                **13,385,000**
                
                
                **1,339**
                
                
                **30,375,584**
                
                
                **(31,417,446**
                **)**
                
                **(1,040,523**
                **)**Stock
                    issued for services
                
                
                100,184
                
                
                10
                
                
                112,524
                
                
                
                
                
                112,534Stock
                    issued for Compensation
                
                
                153,700
                
                
                15
                
                
                101,465
                
                
                
                
                
                101,480Stock
                    issued in exchange for canceling debt
                
                
                2,854,505
                
                
                284
                
                
                1,446,120
                
                
                
                
                
                1,446,404Net
                    Loss October 1, 2006
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    December 31, 2006
                
                
                
                
                
                
                
                
                
                
                
                (466,179
                )
                
                (466,179
                )**Balance
                    December 31, 2006**
                
                
                **16,493,389**
                
                
                **1,649**
                
                
                **32,035,693**
                
                
                **(31,883,625**
                **)**
                
                **153,717**Stock
                    issued for cash
                
                
                500,000
                
                
                50
                
                
                124,950
                
                
                
                
                
                125,000Stock
                    issued for services
                
                
                359,310
                
                
                36
                
                
                235,042
                
                
                
                
                
                235,078Stock
                    issued for Compensation
                
                
                143,920
                
                
                14
                
                
                88,400
                
                
                
                
                
                88,414Stock
                    issued in exchange for canceling debt
                
                
                500,000
                
                
                50
                
                
                124,950
                
                
                
                
                
                125,000Net
                    Loss January 1, 2007
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                -through
                    March 31, 2007
                
                
                
                
                
                
                
                
                
                
                
                (515,624
                )
                
                (515,624
                )**Balance
                    March 31, 2007**
                
                
                **17,996,619**
                
                **$**
                **1,800**
                
                **$**
                **32,609,035**
                
                **$**
                **(32,399,249**
                **)**
                **$**
                **211,585**
 The
        accompanying notes are an integral part of these financial
        statements
 5
 **BIO-MATRIX
                  SCIENTIFIC GROUP, INC. AND SUBSIDIARY****(FORMERLY
                  TASCO INTERNATIONAL, INC.)****(
                  A Development stage Company)****Consolidated
                  Statements of Cash Flows**
                **(Unaudited)**
 
 **October
                  6, 1998****(inception)****6
                  Months Ended**
              
              
              **6
                  Months Ended**
              
              
              **3
                  Months Ended**
              
              
              **3
                  Months Ended**
              
              
              **through****March
                  31,**
              
              
              **March
                  31,**
              
              
              **March
                  31,**
              
              
              **March
                  31,**
              
              
              **March
                  31,****2007**
              
              
              **2006**
              
              
              **2007**
              
              
              **2006**
              
              
              **2007****CASH
                  FLOWS FROM OPERATING ACTIVITIES**Net
                  (loss)
              
              $
              (981,804
              )
              $
              (1,870
              )
              $
              (515,624
              )
              
              (1,632
              )
              $
              (32,399,250
              )Adjustments
                  to reconcile net loss to net cash (used in) providedby
                  operating activities:Impairment
                  of goodwill and intangible asset
              
              
              -
              
              
              
              
              
              
              
              
              
              
              
              29,777,222Depreciation
                  expense
              
              
              667
              
              
              -
              
              
              333
              
              
              -
              
              
              1,000Stock
                  issued for compensation
              
              
              189,894
              
              
              -
              
              
              88,414
              
              
              -
              
              
              774,894Stock
                  issued for services
              
              
              347,612
              
              
              -
              
              
              235,078
              
              
              -
              
              
              1,107,362Cancellation
                  of Debt
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              (5,443
              )Stock
                  issued to cancel debt plus accrued interest
              
              
              376,209
              
              
              
              
              
              125,000
              
              
              
              
              
              376,209Changes
                  in operating assets and liabilities:
              
              
              
              
              
              
              
              
              
              
              
              -(Increase)
                  decrease in receivables
              
              
              (3,000
              )
              
              
              
              
              (2,926
              )
              
              
              
              
              (3,000
              )(Increase)
                  decrease in prepaid expenses
              
              
              (3,520
              )
              
              
              
              
              (23,727
              )
              
              
              
              
              (23,727
              )Increase
                  (Decrease) in Accounts Payable
              
              
              (87,134
              )
              
              (1,600
              )
              
              (50,278
              )
              
              (1,600
              )
              
              3,945Increase
                  (Decrease) in Accrued Expenses
              
              
              9,976
              
              
              -
              
              
              14,805
              
              
              -
              
              
              27,804(
                  Increase) Decrease in Deposits
              
              
              3,401
              
              
              
              
              
              3,401
              
              
              
              
              
              (25,726
              )***Net
                  Cash Provided by (Used in) Operating
                  Activities***
              
              
              **(147,699**
              **)**
              
              **(3,470**
              **)**
              
              **(125,524**
              **)**
              
              **(3,232**
              **)**
              
              **(388,710**
              **)****CASH
                  FLOWS FROM INVESTING ACTIVITIES**Purchases
                  of fixed assets
              
              
              (24,847
              )
              
              -
              
              
              -
              
              
              -
              
              
              (365,737
              )Purchases
                  of Intangible assets
              
              
              
              
              
              -
              
              
              -
              
              
              -
              
              
              (29,777,222
              )***Net
                  Cash Provided by (Used in) Investing
                  Activities***
              
              
              **(24,847**
              **)**
              
              **-**
              
              
              **-**
              
              
              **-**
              
              
              **(30,142,959**
              **)****CASH
                  FLOWS FROM FINANCING ACTIVITIES**Common
                  stock issued for cash
              
              
              50
              
              
              
              
              
              50
              
              
              
              
              
              1,328Additional
                  paid in Capital
              
              
              124,950
              
              
              -
              
              
              124,950
              
              
              -
              
              
              29,161,288Principal
                  borrowings on notes
              
              
              172,610
              
              
              -
              
              
              133,238
              
              
              -
              
              
              321,562Net
                  borrowings from related parties
              
              
              -
              
              
              3,500
              
              
              -
              
              
              -
              
              
              1,195,196***Net
                  Cash Provided by (Used in) Financing
                  Activities***
              
              
              **297,610**
              
              
              **3,500**
              
              
              **258,238**
              
              
              **-**
              
              
              **30,679,374*****Net
                  Increase (Decrease) in Cash***
              
              
              **125,064**
              
              
              **30**
              
              
              **132,714**
              
              
              **(3,232**
              **)**
              
              **147,705*****Cash
                  at Beginning of Period***
              
              
              **22,641**
              
              
              **-**
              
              
              **14,991**
              
              
              **3,261**
              
              
              **-*****Cash
                  at End of Period***
              
              **$**
              **147,705**
              
              
              **-**
              
              $
              **147,705**
              
              
              **30**
              
              
              **147,705*****Supplemental
                  Cash Flow Disclosures:***Cash
                  paid during period for interest
              
              $
              -
              
              
              -
              
              
              
              
              $
              -
              
              $
              -Cash
                  paid during period for taxes
              
              $
              -
              
              
              -
              
              
              
              
              $
              -
              
              $
              800
  The
        accompanying notes are an integral part of these financial
        statements
 6
 BIO-MATRIX
        SCIENTIFIC GROUP, INC. AND SUBSIDIARY
 (A
        Development Stage Company)
 Notes
        to
        consolidated Financial Statements
 As
        of
        March 31, 2007
 
 NOTE
        1.
        ORGANIZATION AND DESCRIPTION OF BUSINESS
 
 Bio-Matrix
        Scientific Group, Inc. (“Company”) was organized October 6, 1998, under the laws
        of the State of Delaware as Tasco International, Inc.
 
 The
        Company is in the development stage. From October 6, 1998 to June 3, 2006
        its
        activities have been limited to capital formation, organization, and development
        of its business plan to provide production of visual content and other digital
        media, including still media, 360-degree images, video, animation and audio
        for
        the Internet.
 
 On
        June 3,
        2006 the Company abandoned its efforts in the field of digital media production
        when it acquired 100% of the share capital of Bio-Matrix Scientific Group,
        Inc.,
        a Nevada corporation (“BMSG”).
 
 Bio-Matrix
        Scientific Group, Inc. is a development stage company in the business of
        designing, developing, and marketing medical devices, specifically disposable
        instruments used in stem cell extraction and tissue transfer procedures and
        operating cryogenic cellular storage facilities, specifically stem cell banking
        facilities. BMSG is the Company’s only subsidiary and operating entity at this
        time. On August 25, 2006, the Company amended its certificate of incorporation
        in order that it may change its name to Bio-Matrix Scientific Group,
        Inc.
  NOTE
        2.
        SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
 A.
        BASIS
        OF ACCOUNTING
 
 The
        consolidated financial statements have been prepared using the accrual basis
        of
        accounting. Under the accrual basis of accounting, revenues are recorded
        as
        earned and expenses are recorded at the time liabilities are incurred. The
        Company has adopted a September 30, year-end.
 
 B.
        USE OF
        ESTIMATES
 
 The
        preparation of consolidated financial statements in conformity with generally
        accepted accounting principles requires management to make estimates and
        assumptions that affect the reported amounts of assets and liabilities and
        disclosure of contingent assets and liabilities at the date of the financial
        statements and the reported amounts of revenues and expenses during the
        reporting period. Actual results could differ from those estimates.
 
 C.
        DEVELOPMENT STAGE
 
 The
        Company is a development stage company that, through its wholly owned subsidiary
        devotes substantially all of its efforts in the development of its plan to
        operate in the field of the development, manufacture and marketing of medical
        devices and the operation of cellular storage facilities, specifically stem
        cell
        banking facilities.
  D.
        CASH
        EQUIVALENTS
  The
        Company considers all highly liquid investments with a maturity of three
        months
        or less when purchased to be cash equivalents.
 
 E.
        PROPERTY AND EQUIPMENT
 
 Property
        and equipment are recorded at cost. Maintenance and repairs are expensed
        in the
        year in which they are incurred. Expenditures that enhance the value of property
        and equipment are capitalized.
 
 The
        Company has depreciated property and equipment by the straight-line method
        over
        the useful life.
  F.
        INCOME
        TAXES
  7
 Income
          taxes are provided in accordance with Statement of Financial accounting
          Standards No. 109 (SFAS 109), Accounting for Income Taxes. A deferred tax
          asset
          or liability is recorded for all temporary differences between financial
          and tax
          reporting and net operating loss carryforwards. Deferred tax expense (benefit)
          results from the net change during the year of deferred tax assets and
          liabilities.
 Deferred
        tax assets are reduced by a valuation allowance when, in the opinion of
        management, it is more likely than not that some portion of all of the deferred
        tax assets will be not realized. Deferred tax assets and liabilities are
        adjusted for the effects of changes in tax laws and rates on the date of
        enactment.
 
 G.
        BASIC
        EARNINGS (LOSS) PER SHARE
 
 In
        February 1997, the FASB issued SFAS No. 128, "Earnings Per Share", which
        specifies the computation, presentation and disclosure requirements for earnings
        (loss) per share for entities with publicly held common stock. SFAS No. 128
        supersedes the provisions of APB No. 15, and requires the presentation of
        basic
        earnings (loss) per share and diluted earnings (loss) per share. The Company
        has
        adopted the provisions of SFAS No. 128 effective October 6, 1998
        (inception).
 
 Basic
        net
        loss per share amounts is computed by dividing the net income by the weighted
        average number of common shares outstanding. Diluted earnings per share are
        the
        same as basic earnings per share due to the lack of dilutive items in the
        Company.
 
 H.
        VALUATION OF GOODWILL
 
 In
        accordance with SFAS No. 142, goodwill and other intangible assets with
        indefinite lives are not amortized, they are instead tested for impairment
        annually or whenever events or changes in circumstances indicate that the
        asset
        may be impaired. The Company performed an evaluation of goodwill and intangible
        assets in the fourth quarter of the twelve months ended September 30, 2006
        which
        resulted in impairment charges of $29,777,222. The Company currently has
        $0 of
        goodwill.
  NOTE
        3.
        Property and equipment
  Property
        and equipment as of March 31, 2007 consists of the following:
 Acquisition
                    cost:Production
                    Equipment
                
                US$
                93,315Production
                    Cleanroom
                
                
                78,264Leasehold
                    improvement
                
                
                188,981Office
                    equipment
                
                
                3,057Computer
                
                
                2,120Subtotal
                
                
                365,737Less
                    accumulated depreciation
                
                
                (1000
                )Total
                
                US$
                364,737
  NOTE
        4.
        WARRANTS AND OPTIONS
 
 On
        July
        17, 2006 the Company signed a public relations agreement with OTCFN which
        called
        for the issuance of an option agreement for 200,000 options exercisable at
        $4.50
        per share. These options expired unexercised six months from the date of
        execution of the agreement
  NOTE
            5.
            GOING CONCERN
 
 The
            accompanying consolidated financial statements have been prepared assuming
            that
            the Company will continue as a going concern. The Company generated net
            losses
            of $32,399,250 during the period from October 6, 1998 (inception) through
            March
            31, 2007. This condition raises substantial doubt about the Company's
            ability to
            continue as a going concern. The Company's continuation as a going concern
            is
            dependent on its ability to meet its obligations, to obtain additional
            financing
            as may be required and ultimately to attain profitability. The financial
            statements do not include any adjustments that might result from the
            outcome of
            this uncertainty. Management
            plans to raise additional funds through debt or equity offerings. Management
            has
            yet to decide what type of offering the Company will use or how much
            capital the
            Company will raise. There is no guarantee that the Company will be able
            to raise
            any capital through any type of offerings.
 8
 NOTE
        6.
        INCOME TAXES
 As
                    of March 31, 2007Deferred
                    tax assets:Net
                    operating tax carry forwards
                
                $
                11,015,745Other
                
                
                0Gross
                    deferred tax assets
                
                
                11,,015,745Valuation
                    allowance
                
                
                (11,015,745
                )Net
                    deferred tax assets
                
                $
                0
  Realization
        of deferred tax assets is dependent upon sufficient future taxable income
        during
        the period that deductible temporary differences and carryforwards are expected
        to be available to reduce taxable income. As the achievement of required
        future
        taxable income is uncertain, the Company recorded a valuation allowance.
        In
        addition, the acquisition of BMSG has resulted in a change of control. Internal
        Revenue Code Sec 382 limits the amount of income that may be offset by net
        operating loss (NOL) carryovers after an ownership change.
 
 NOTE
        7.
        SCHEDULE OF NET OPERATING LOSSES
 1998
                    Net Operating Loss
                
                $
                (295
                )1999
                    Net Operating Loss
                
                
                (367
                )2000
                    Net Operating Loss
                
                
                (11,028
                )2001
                    Net Operating Loss
                
                
                (4,257
                )2002
                    Net Operating Loss
                
                
                (4,328
                )2003
                    Net Operating Loss
                
                
                (7,974
                )2004
                    Net Operating Loss
                
                
                (6,667
                )2005
                    Net Operating Loss
                
                
                (31,382,530
                )Three
                    Months Ended December 31, 2006 Net Operating Loss
                
                
                (466,179
                )Three
                    Months Ended March 31, 2007 Net Operating Loss
                
                
                (515,624
                )Net
                    Operating Loss
                
                $
                (32,399,250
                )
  As
        of
        March 31, 2007 the Company has a net operating loss carryforward of
        approximately $32,399,250 which will expire 20 years from the date the loss
        was
        incurred.
 
 NOTE
        8.
        RELATED PARTY TRANSACTION
 
 Until
        July
        3, 2006, a former director has provided office services without charge. Such
        costs are immaterial to the financial statements and, accordingly, have not
        been
        reflected therein.
 
 The
        Company was loaned $5,300 from a related party without repayment terms and
        with
        no interest being charged. This Loan was forgiven as part of the Purchase
        Agreement involving the Company’s purchase of Bio-Matrix Scientific Group Inc.
        (Nevada).
 
 On
        July 3,
        2006, the Company acquired 100% of the share capital of BMSG from BMXP Holdings,
        Inc., formerly named Bio Matrix Scientific Group, Inc. (See Note
        12).
 
 David
        R.
        Koos, the Chairman, CEO and President of the Company, is, and at the time
        of the
        acquisition was, the Chairman and Chief Executive Officer of BMXP Holdings
        Inc.
        as well as beneficial owner of 24% of the share capital of BMXP Holdings,
        Inc.
        Brian Pockett, Vice President, COO and Director of the Company, is , and
        at the
        time of the acquisition was, Chief Operating Officer, Managing Director and
        a
        Director of BMXP Holdings Inc. as well as beneficial owner of 14% of the
        share
        capital of BMXP Holdings, Inc.
 9
 On
        October
        11, 2006, the Company entered into an Agreement with BMXP Holdings, Inc (“BMXP”)
        (“Agreement”) pursuant to which the Company issued to BMXP 1,462,570 common
        shares of the Company on or prior to October 12, 2006. This issuance will
        constitute full satisfaction of the amount of $1,191,619 plus any accrued
        and
        unpaid interest, owed to BMXP by the Company.
 
 As
        further
        consideration to BMXP for entering into this Agreement and abiding by the
        terms
        and conditions thereof, at any time within a period of 365 days from the
        date of
        the Agreement, BMXP shall have the right, upon written demand to the Company
        (“Registration Demand”), to cause the Company, within ninety days of the
        Registration Demand, to prepare and file with the United States Securities
        and
        Exchange Commission (“SEC”) a registration statement to register under the
        Securities Act of 1933, as amended, 11,462,570 common shares of the Company
        (including the shares issued pursuant to this Agreement) owned by BMXP
        (“Registerable Securities”), in order that the Registerable Securities may be
        distributed to BMXP shareholders on a pro rata basis ( based on their ownership
        of common shares of the Company as of a Record Date to be determined by BMXP),
        and use its reasonable best efforts to cause that registration statement
        to be
        declared effective by the SEC. This right may also be exercised by any entity
        to
        which BMXP has transferred ownership of the Registerable Securities in trust
        for
        the BMXP Record Shareholders.
  NOTE
        9.
        STOCK TRANSACTIONS
 
 Transactions,
        other than employees' stock issuance, are in accordance with paragraph 8
        of SFAS
        123. Thus issuances shall be accounted for based on the fair value of the
        consideration received. Transactions with employees' stock issuance are in
        accordance with paragraphs (16-44) of SFAS 123. These issuances shall be
        accounted for based on the fair value of the consideration received or the
        fair
        value of the equity instruments issued, or whichever is more readily
        determinable.
 
 On
        August
        29, 2005 the Company split its common stock ten for one (10:1) from 1,278,000
        to
        12,780,000 shares outstanding. All stock transactions have been retroactively
        restated to reflect the ten for one stock split.
 
 On
        October
        6, 1998, the Company issued 1,000,000 shares of common stock for cash at
        $0.0001
        per share.
 
 On
        October
        9, 1998, the Company issued 1,300,000 shares of common stock for cash at
        $0.001
        per share.
 
 On
        October
        12, 1998, the Company issued 190,000 shares of common stock for cash at $0.001
        per share.
 
 On
        April
        1, 1999, the Company issued 290,000 shares of common stock for cash at $0.001
        per share.
  On
        October
        19, 1999, the Company issued 10,000,000 shares of common stock for cash at
        $0.01
        per share.
 
 On
        June
        13, 2006 the Company cancelled 10,000,000 shares of common stock belonging
        to
        the Company’s former Chairman
 
 On
        June
        13, 2006 the Company issued 10,000,000 shares of common stock into Escrow
        in
        connection with the acquisition of BSMG.
 
 On
        August
        28, 2006 the Company issued 300,000 shares of common stock to consultants
        for
        services. Initially, 600,000 shares were issued in error, and 300,000shares
        were
        subsequently cancelled October 17, 2006.
 
 On
        September 14, 2006 the Company issued 300,000 shares of common stock to
        management pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE
        AND
        CONSULTANTS STOCK COMPENSATION PLAN
 
 On
        September 14, 2006 the Company issued 5,000 shares of common stock to
        consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC.
        2006
        EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.
 
 On
        October, 6, 2006 the Company issued 8,850 shares of common stock to consultants
        for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE
        AND CONSULTANTS STOCK COMPENSATION PLAN.
 
 On
        October
        11, 2006 the Company issued 43,000 shares of common stock to consultants
        for
        services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE
        AND
        CONSULTANTS STOCK COMPENSATION PLAN.
 
 On
        October
        11, 2006, the Company shall issued 1,462,570 common shares of the Company
        to
        BMXP in full satisfaction of the amount of $1,191,619 plus accrued and unpaid
        interest, owed to BMXP Holdings, Inc. by the Company.
 10
 On
          November 10, 2006 the Company issued 100,000 shares of common stock to
          management pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE
          AND
          CONSULTANTS STOCK COMPENSATION PLAN.
  On
        November 10, 2006 the Company issued 25,000 shares of common stock to
        consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC.
        2006
        EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.
 
 On
        December 5, 2006 the Company issued 8,334 shares of common stock to a consultant
        for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE
        AND CONSULTANTS STOCK COMPENSATION PLAN.
 
 On
        December 5, 2006 the Company issued 1,391,935 shares of common stock to
        Bio-Technology Partners Business Trust which constituted full satisfaction
        of
        the amount of $246,744 plus accrued interest owed by the Company to
        Bio-Technology Partners Business Trust.
  On
        December 14, 2006 the Company issued 68,700 shares of common stock to
        management, employees and consultants for services pursuant to the TASCO
        HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION
        PLAN.
 
 During
        the
        quarter ended March 31, 2007 the Company issued 143,920 shares of common
        stock
        to management and employees as compensation pursuant to the TASCO HOLDINGS
        INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION
        PLAN.
 
 During
        the
        quarter ended March 31, 2007 the Company issued 359,310 to consultants for
        services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE
        AND
        CONSULTANTS STOCK COMPENSATION PLAN.
 
 On
        March
        9, 2007 the Company issued 500,000 shares of common stock to Bio-Technology
        Partners Business Trust which constituted full satisfaction of the amount
        of
        $125,000 owed by the Company to Bio-Technology Partners Business
        Trust.
 
 During
        the
        quarter ended March 31, 2007 the Company issued 500,000 shares of common
        stock
        for cash consideration of $125,000.
 
 On
        April
        4, 2007, the Company issued 240,666 common shares for cash consideration
        of
        $60,166.
 
 On
        April
        4, 2007, the Company issued 27,033 Shares to two purchasers as consideration
        for
        services rendered valued at $6,758.
 
 On
        April
        4, 2007, 985, 168 shares of the Company’s common stock were issued to Bombardier
        Pacific Ventures in full satisfaction of $246,292 owed by the Company to
        Bombardier Pacific Ventures. David R. Koos, the Company’s Chairman of the Board
        of Directors, President, CEO, Secretary, and Acting CFO, is the sole beneficial
        owner of Bombardier Pacific Ventures
 
 NOTE
        10.
        STOCKHOLDERS' EQUITY
 
 The
        stockholders' equity section of the Company contains the following classes
        of
        capital stock as of March 31, 2007:
 
 *
        Preferred stock, $ 0.0001 par value; 20,000,000 shares authorized: -0- shares
        issued and outstanding.
 
 *
        Common
        stock, $ 0.0001 par value; 80,000,000 shares authorized: 17,996,619 shares
        issued and outstanding.
 
 NOTE
        11.
        COMMITMENTS AND CONTINGENCIES
 
 On
        August
        3, 2005, BMSG entered into an agreement to lease a 14,562 square foot facility
        for use as a cellular storage facility at a rate of:
 $18,931
        per month for the twelve months ended November 30, 2006,
 $19,498
        per month for the twelve months ended November 30, 2007,
 $20,084
        per month for the twelve months ended November 30, 2008,
 $20,687
        per month for the twelve months ended November 30, 2009, and
 $21,307
        per month for the twelve months ended November 30, 2010.
 The
        lease
        is for a period of five years commencing on December 1, 2005 and expiring
        on
        November 30, 2010. The lease contains a renewal option enabling the Company
        to
        renew the lease for an additional five years. The Company is also responsible
        to
        pay its pro rata portion of common charges such as property taxes and
        insurance.
  11
 
 Minimum
            Lease Commitments
 For
            the
            fiscal years ended on September 30,
 2007
              
              $
              232,8422008
              
              $
              239,9362009
              
              $
              247,0382010
              
              $
              254,4442011
              
              $
              42,614
  Since
          the
          signing of this lease, BMSG has been improving this facility and has made
          substantial progress toward creating a cGMP (Good Manufacturing Practices)
          and cGTP
          (Good
          Tissue Practices) compliant facility specifically designed for the cryogenic
          storage of stem cells, medical device engineering, stem cell research and
          stem
          cell specimen processing laboratories.
  The
        Company expects to have the facility licensed by the State of California
        and
        registered with the FDA. Concurrently, the Company has been developing the
        policies and procedures needed for processing stem cells for cryogenic
        storage.
 
 NOTE
        12.
        ACQUISITION OF BIO-MATRIX SCIENTIFIC GROUP (NEVADA).
 
 On
        June
        14, 2006, the Company and Bio-Matrix Scientific Group, Inc., a Delaware
        corporation (the “Seller”) entered into a Stock Purchase Agreement (the
“Acquisition Agreement”).
 
 Under
        the
        terms of the Acquisition Agreement and pursuant to a separate Escrow Agreement
        between the Company and the Seller, The Company delivered to the Escrow Agent
        the sum of 10,000,000 shares of the Company’s common stock and other corporate
        and financial records and the Seller delivered to the Escrow Agent 25,000
        shares
        of the common stock of BSMG., a Nevada corporation (the “Subsidiary”). As a part
        of the transaction and pursuant to the terms of the Acquisition Agreement
        and
        Stock Cancellation Agreement between the parties and John Lauring, the Company’s
        former Chairman and Chief Executive Officer, John Lauring returned 10,000,000
        shares of the Company held and owned by him for cancellation.
 
 On
        June
        14, 2006, the Company’s officers and directors resigned their positions and
        elected Dr. David R. Koos and Mr. Brian Pockett as in-coming Directors of
        the
        Registrant. Following their election and the reconstruction of the Board
        of
        Directors, the Registrant’s Board of Directors elected Dr. David R. Koos as
        Chief Executive Officer and President and Mr. Brian Pockett as Chief Operating
        Officer and Vice President on June 19, 2006.
 
 On
        July 3,
        2006, the Acquisition Agreement closed and Company acquired the twenty-five
        thousand (25,000) shares of the Common Stock of the Subsidiary from the Seller
        in exchange for the payment of the purchase price of 10,000,000 shares of
        the
        common stock of the Company and the 10,000,000 shares of the Company owned
        and
        held by John Lauring were returned to the Company for cancellation. At that
        time, the Escrow Agent released all stock certificates and certain other
        corporate and financial books and records held pursuant to the Escrow
        Agreement.
  As
        a
        result of the Acquisition Agreement, the Subsidiary became a wholly owned
        subsidiary of the Company and the Seller became the holder of approximately
        78.24% of the outstanding common stock of the Registrant.
 
 On
        July 3,
        2006, the Company changed its principal offices from 23 Brigham Road, Worcester
        MA 01609 to 8885 Rehco Road, San Diego, California 92121
 
 NOTE
        13.
        TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK
        COMPENSATION PLAN
 
 On
        July
        25, 2006 the Company adopted the TASCO HOLDINGS INTERNATIONAL, INC. 2006
        EMPLOYEE AND CONSULTANTS STOCK COMPENSATIONPLAN (“the Plan”) which provides for
        the issuance of up to 1,500,000 authorized but unissued shares of Common
        Stock
        to eligible employees and consultants for services rendered (“Award Shares” or
“Awards”). These Award Shares were registered with the Securities and Exchange
        Commission (“Commission”) on Form S-8 filed with the Commission on August 8,
        2006. This Plan shall terminate on July 15, 2016.
 
 Award
        Shares may be issued to Eligible Persons (The term "Eligible Person" means
        any
        natural person who, at a particular time, is an employee, officer, director,
        consultant, or advisor of the Company or any Parent or Subsidiary of the
        Company; provided that, in the case of consultants or advisors such services
        are
        not in connection with the offer and sale of securities in a capital-raising
        transaction and /or such services are not intended to directly or indirectly
        promote or maintain a market for the Company ’s securities) in any of the
        following instances:
  (i)
        as a
        bonus for services previously rendered and compensated, in which case the
        recipient of the Award Shares shall not be required to pay any consideration
        for
        such Award Shares, and the value of such Award Shares shall be the Fair Market
        Value of such Award Shares on the date of grant; or
 
 (ii)
        as
        compensation for the previous performance or future performance of services
        or
        attainment of goals, in which case the recipient of the Award Shares shall
        not
        be required to pay any consideration for such Award Shares (other than the
        prior
        performance of his services or the assumption of the obligation of future
        performance of services ).
 12
 The
          Plan
          is currently administered by the Plan Committee, which currently consists
          of the
          entire Board of Directors of the Company, and which has sole and absolute
          discretion to interpret and determine the effect of all matters and questions
          relating to this Plan.
 
 The
          Plan
          Committee has the full and final authority in its sole discretion, at any
          time
          and from time-to-time, subject only to the express terms, conditions and
          other
          provisions of the Articles of Incorporation of the Company and this Plan,
          and
          the specific limitations on such discretion set forth herein, to:
 
 (i)
          Designate the Eligible Persons or classes of Eligible Persons eligible
          to
          receive Awards from among the Eligible Persons;
 (ii)
          Grant
          Awards to such selected Eligible Persons or classes of Eligible Persons
          in such
          form and amount (subject to the terms of the Plan) as the Plan Committee
          shall
          determine;
 
 (iii)
        Interpret the Plan, adopt, amend and rescind rules and regulations relating
        to
        the Plan, and make all other determinations and take all other action necessary
        or advisable for the implementation and administration of the Plan;
        and
 
 (iv)
        Delegate all or a portion of its authority to one or more directors of the
        Company who are executive officers of the Company, subject to such restrictions
        and limitations (such as the aggregate number of shares of Common Stock that
        may
        be awarded) as the Plan Committee may decide to impose on such delegate
        directors.
  As
        of
        March 31, 2007 -- 1,362,114 shares have been issued pursuant to the
        Plan
  **Number
                    of****Shares****As
                    of March 31, 2007:**Granted
                
                
                1,362,114*Remaining
                    shares available for issuance under the Plan as of March 31,
                    2007
                
                
                137,886
  *Does
        not
        include 300,000 shares which were issued erroneously and subsequently
        cancelled
 
 NOTE
        14.
        SUBSEQUENT EVENTS.-
 
 On
        April
        4, 2007, the Company issued 240,666 common shares (“Shares”) for cash
        consideration of $60,166.
 
 The
        net
        proceeds of the sale of shares sold for cash consideration, which were $60,166,
        will be utilized for general working capital purposes.
 
 On
        April
        4, 2007, the Company issued 27,033 Shares to two purchasers as consideration
        for
        services rendered valued at $6,758.
 
 On
        April
        4, 2007, 985, 168 shares of the Company’s common stock were issued to Bombardier
        Pacific Ventures in full satisfaction of $246,292 owed by the Company to
        Bombardier Pacific Ventures. David R. Koos, the Company’s Chairman of the Board
        of Directors, President, CEO, Secretary, and Acting CFO, is the sole beneficial
        owner of Bombardier Pacific Ventures
  **Item
        2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF
        OPERATIONS.**
 
 **CERTAIN
        FORWARD-LOOKING INFORMATION**
 
 Information
        provided in this Quarterly report on Form 10QSB may contain forward-looking
        statements within the meaning of Section 21E or Securities Exchange Act of
        1934
        that are not historical facts and information. These statements represent
        the
        Company's expectations or beliefs, including, but not limited to, statements
        concerning future and operating results, statements concerning industry
        performance, the Company's operations, economic performance, financial
        conditions, margins and growth in sales of the Company's products, capital
        expenditures, financing needs, as well assumptions related to the forgoing.
        For
        this purpose, any statements contained in this Quarterly Report that are
        not
        statement of historical fact may be deemed to be forward-looking statements.
        These forward-looking statements are based on current expectations and involve
        various risks and uncertainties that could cause actual results and outcomes
        for
        future periods to differ materially from any forward-looking statement or
        views
        expressed herein. The Company's financial performance and the forward-looking
        statements contained herein are further qualified by other risks including
        those
        set forth from time to time in the documents filed by the Company with the
        Securities and Exchange Commission, including the Company's most recent Form
        10KSB for the year ended September 30, 2006.
 13
 **CONDITION
          AND RESULTS OF OPERATIONS THREE MONTHS ENDED MARCH 31, 2007**
 
 Revenues
          were -0- for the quarter ending March 31, 2007 and -0- for the same quarter
          ending March 31, 2006. Net loss were $515,624 for the three months ended
          March
          31, 2007 and $1,632 for the same period ended March 31, 2006.
  **ACQUISITION
        OF WHOLLY OWNED SUSIDIARY**
 
 As
        of the
        acquisition of 100% of the share capital of Bio-Matrix Scientific Group,
        Inc.
        (“BMSG”, a Nevada corporation) on July 3, 2006, Tasco Holdings International,
        Inc. (“Company”) has ceased all activities relating to its historical business
        and adopted the business plan of BMSG.
 
 BMSG
        is
        developmental stage company engaged primarily in the cryogenic storage of
        stem
        cells and the development of medical devices used in live tissue transfer
        and
        stem cell research.
 
 Through
        BMSG, the Company has developed a line of medical devices (approximately
        192
        disposable instruments for use in the plastic surgery field and stem cell
        research). The instruments are designed to be used to harvest adult stem
        cells
        from adipose (fat) tissue. The Company seeks to market and sell these
        instruments to plastic surgeons and to offer the patients of these plastic
        surgeons an opportunity to store stem cells derived from adipose tissue for
        future medical treatments. The Company has not conducted or obtained any
        independent evaluation of the efficacy or likely market interest in using
        these
        instruments. The Company's evaluations have been limited to those conducted
        by
        Company management without the benefit of any independent or third party
        professional evaluation.
 
 Through
        BMSG , the Company is currently constructing what it believes is a state-of-the
        art, FDA good manufacturing practices (cGMP) and good tissue practices (cGTP)
        compliant facility for the processing and cryo-storage (in liquid nitrogen)
        of
        adult stem cells. It anticipates that it will offer a similar service to
        expectant parents by offering to store their newborn's cord blood stem cells
        as
        well. In undertaking these plans, it intend to offer such storage services
        at
        its planned facility. The planned facility is located at 8885 Rehco Road,
        San
        Diego, California 92121 and has approximately 15,000 square feet. The planned
        facility was acquired under a five year lease on December 1, 2005 at a current
        cost of $18,931 per month (plus certain common area costs). Under the terms
        of
        the lease, the lease term may be extended for an additional five year lease
        term
        at the then prevailing market prices.
 
 All
        of the
        Company's current plans and strategy have been developed solely by our officers
        and Directors.
 
 **PLAN
        OF OPERATION**
 
 As
        of
        March 31, 2007 the Company has $147,705 cash on hand and current liabilities
        of
        $353,310 such liabilities consisting of Accounts Payable, Notes Payable,
        Accrued
        Payroll Taxes, and Accrued Interest.
  The
        Company feels it will not be able to satisfy its cash requirements over the
        next
        twelve months and shall be required to seek additional financing.
 
 At
        this
        time, the Company plans to fund its financial needs through operating revenues
        (which cannot be assured) and, if required, through equity private placements
        of
        common stock. (No plans, terms, offers or candidates have yet been established
        and there can be no assurance that the company will be able to raise funds
        on
        terms favorable to the Company or at all.) During the period beginning January
        1, 2007 and ending April 4, 2007, the Company sold 1,752,867 shares of common
        stock at a purchase price of $0.25 per share.
 
 740,666
        of
        the Shares were sold for cash consideration of $185,166 to five
        purchasers.
 The
        net
        proceeds of the sale of shares sold for cash consideration, which were $185,166,
        will be utilized for general working capital purposes. We estimate that these
        net proceeds will not be sufficient to fulfill our capital needs through
        the
        next twelve months.
  27,033
        of
        the Shares were issued to two purchasers as consideration for services rendered
        valued at $6,758.
 985,
        168
        of the Shares were issued to Bombardier Pacific Ventures in full satisfaction
        of
        $246,292 owed by the Company to Bombardier Pacific Ventures on April 4, 2007.
 
 Over
        the
        next 12 months, the Company anticipates opening its stem cell bank and marketing
        its disposable stem cell / tissue management instruments. Furthermore, the
        Company expects to increase the total number of employees by 20 new
        hires.
 14
 **Item
          3. CONTROLS AND PROCEDURES**
  (A)
          Evaluation of Disclosure Controls and Procedures
  As
          of the
          end of the period covered by this report, the Company carried out an evaluation,
          under the supervision and with the participation of David Koos, who is
          the
          Company's Principal Executive Officer/Principal Financial Officer, of the
          effectiveness of the design and operation of the Company's disclosure controls
          and procedures. The Company's disclosure controls and procedures are designed
          to
          provide a reasonable level of assurance of achieving the Company's disclosure
          control objectives. The Company's Principal Executive Officer/Principal
          Financial Officer has concluded that the Company's disclosure controls
          and
          procedures are, in fact, effective at this reasonable assurance level as
          of the
          period covered.
  (B)
        Changes in Internal Controls over Financial Reporting
  In
        connection with the evaluation of the Company's internal controls during
        the
        period commencing on January 1, 2007 and ending March 31, 2007, David Koos,
        who
        is both the Company's Principal Executive Officer and Principal Financial
        Officer has determined that there are no changes to the Company's internal
        controls over financial reporting that has materially affected, or is reasonably
        likely to materially effect, the Company's internal controls over financial
        reporting.
 
 **PART
        II.**
  **Item
        1: LEGAL PROCEEDINGS**
 
 None
 
 **Item
        2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
        PROCEEDS**
 
 On
        March
        9, 2007 the Company issued 500,000 shares of common stock to Bio-Technology
        Partners Business Trust which constituted full satisfaction of the amount
        of
        $125,000 owed by the Company to Bio-Technology Partners Business
        Trust.
 
 No
        underwriters were retained to serve as placement agents for the sale. The
        500,000 shares of common stock were sold directly through the management
        of the
        Company. No commission or other consideration was paid in connection with
        the
        sale of the 500,000 shares of common stock.
 
 The
        offer
        and sale of the 500,000 shares of common stock was exempt from the registration
        provisions of the Securities Act of 1933, as amended, by reason of Section
        4(2)
        thereof.
 
 During
        the
        period beginning January 1, 2007 and ending April 4, 2007, the Company sold
        1,752,867 restricted shares (the "Shares") of common stock, at a purchase
        price
        of $0.25 per share.
 
 740,666
        of
        the Shares were sold for cash consideration of $185,166 to five
        purchasers.
 The
        net
        proceeds of the sale of shares sold for cash consideration, which were $185,166,
        will be utilized for general working capital purposes. The Company estimates
        that these net proceeds will not be sufficient to fulfill our capital needs
        through the next twelve months.
 
 27,033
        of
        the Shares were issued to two purchasers as consideration for services rendered
        valued at $6,758.
 
 985,
        168
        of the Shares were issued to Bombardier Pacific Ventures in full satisfaction
        of
        $246,292 owed by the Company to Bombardier Pacific Ventures on April 4, 2007.
        David R. Koos, the Company’s Chairman of the Board of Directors, President, CEO,
        Secretary, and Acting CFO, is the sole beneficial owner of Bombardier Pacific
        Ventures.
 
 No
        underwriters were retained to serve as placement agents for the sale. The
        Shares
        were sold directly through the management of the Company. No commission or
        other
        consideration was paid in connection with the sale of the Shares
 
 The
        offer
        and sale of the Shares was exempt from the registration provisions of the
        Securities Act of 1933, as amended, by reason of Section 4(2) thereof.
 15
 **Item
          3. DEFAULTS UPON SENIOR SECURITIES**
 
 None.
  **Item
          4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**
 
 None.
 
 **Item
          5. OTHER INFORMATION**
 
 None.
  **Item
        6. EXHIBITS**
  31.1
              Certification
                  of Chief Executive Officer31.2
              Certification
                  of Acting Chief Financial Officer32.1
              Certification
                  of Chief Executive Officer under Section 906 of the Sarbanes-Oxley
                  Act of
                  2002.32.2
              Certification
                  of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley
                  Act of 2002.
 
 
  
 
 **SIGNATURES**
 
 In
        accordance with the requirements of the Exchange Act, the Company caused
        this
        report to be signed on its behalf by the undersigned, thereunto duly
        authorized.
  Bio
                    Matrix Scientific Group, Inc.a
                    Delaware corporationBy:
                /s/
                    David R. KoosDavid
                    R. KoosChief
                    Executive OfficerDate:
                    March 10, 2007


16